Aparna A Wagle Shukla

Aparna A Wagle Shukla, M.D.

Professor Of Neurology Director, Clinical Trials

Department: MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone: (352) 273-5550

About Aparna A Wagle Shukla

Dr. Wagle Shukla is an Associate Professor in the movement disorders division of the Department of Neurology at the University of Florida. Dr. Wagle Shukla received training in movement disorders from the University of Toronto, Canada and has been a faculty at the University of Florida for the last ten years.

Dr. Wagle Shukla’s goal of practice is to provide the highest level of quality care to patients with Parkinson’s disease, dystonia, tremors, chorea, and many other movement disorders. She is experienced and proficient in the administration of botulinum toxin for dystonia, sialorrhea, migraines, and spasticity. The University of Florida is world renowned for deep brain stimulation (DBS) surgery. DBS is a highly effective treatment for patients with Parkinson’s disease, essential tremor, dystonia, Tourette syndrome, and Obsessive Compulsive Disorder. She plays an active role in the DBS program at the University of Florida. She provides expertise for microelectrode recording during DBS surgeries for accurate placement of the electrode in the brain. She also provides outpatient care for these patients through DBS programming.

Teaching Profile

Courses Taught
2018
MDC7124 Family Med/Geriatrics
2021
MDC7800 Neurology Clerkship

Board Certifications

  • Neurology
    American Board of Psychiatry and Neurology

Clinical Profile

Specialties
  • Neurology
Areas of Interest
  • Dystonia
  • Movement – uncontrollable
  • Sydenham chorea
  • Tourette syndrome and tic disorders
  • Tremor disorders

Research Profile

Dr. Wagle Shukla is committed to research in movement disorders in many ways. She is the director for transcranial magnetic stimulation (TMS) Laboratory and the co-director for clinical trials in essential tremor, dystonia, Parkinson’s disease, Huntington’s disease and Tourette syndrome to develop better treatments for these conditions. Dr. Wagle Shukla has been appointed as the Director for the Neurophysiology core research lab at the Fixel Institute for Neurological Diseases. The mission of the core lab is to advance the electrophysiological understanding of tremors, dystonia, myoclonus, and psychogenic movement disorders. She is the clinical director for Tyler’s Hope Foundation for Dystonia and a member of Tremor Research Group.

Dr. Wagle Shukla is working on many projects to elucidate the mechanisms underlying dystonia, dystonia treatments and develop novel treatments for dystonia, particularly involving the use of noninvasive repetitive TMS in conjunction with oral pharmacological therapies, botulinum toxin injections, and DBS surgery. She is working on increasing the applications of rehabilitation therapies in the field of movement disorders. Similarly, Dr. Wagle Shukla is also working on many tremor disorders, including essential tremor, Parkinson’s disease, dystonic tremor, and orthostatic tremor. She has been awarded numerous grants for this research through the Dystonia Coalition, Dystonia Medical Research Foundation, CTSI at UF (National Institute of Health sponsored KL2 grant), Brain and Spinal Cord Injury Research Trust Fund, Blepharospasm Research Foundation, National Organization for Rare Disorders and the National Institute of Health (NINDS K23 Grant). She has made several international presentations on her research and has more than 70 publications in many prestigious peer-reviewed journals including, Brain, Neurology, Journal of Neurology and Neurosurgery and Movement Disorders.

Open Researcher and Contributor ID (ORCID)

0000-0002-9757-9973

Publications

2022
Rationale and Evidence for Peripheral Nerve Stimulation for Treating Essential Tremor
Tremor and Other Hyperkinetic Movements. 12(1) [DOI] 10.5334/tohm.685. [PMID] 35949227.
2022
Reduction of neuronal hyperexcitability with modulation of T-type calcium channel or SK channel in essential tremor.
International review of neurobiology. 163:335-355 [DOI] 10.1016/bs.irn.2022.02.008. [PMID] 35750369.
2022
TANGO2 Mutation: A Genetic Cause of Multifocal Combined Dystonia.
Movement disorders clinical practice. 9(3):380-382 [DOI] 10.1002/mdc3.13400. [PMID] 35402644.
2022
The use of virtual reality to modify and personalize interior home features in Parkinson’s disease.
Experimental gerontology. 159 [DOI] 10.1016/j.exger.2022.111702. [PMID] 35038568.
2021
Case Report: Deep Brain Stimulation of the Nucleus Basalis of Meynert for Advanced Alzheimer’s Disease.
Frontiers in human neuroscience. 15 [DOI] 10.3389/fnhum.2021.645584. [PMID] 34122027.
2021
Comparative connectivity correlates of dystonic and essential tremor deep brain stimulation.
Brain : a journal of neurology. 144(6):1774-1786 [DOI] 10.1093/brain/awab074. [PMID] 33889943.
2021
Corrigendum: Proceedings of the Eighth Annual Deep Brain Stimulation Think Tank: Advances in Optogenetics, Ethical Issues Affecting DBS Research, Neuromodulatory Approaches for Depression, Adaptive Neurostimulation, and Emerging DBS Technologies.
Frontiers in human neuroscience. 15 [DOI] 10.3389/fnhum.2021.765150. [PMID] 34658825.
2021
Deep brain stimulation programming strategies: segmented leads, independent current sources, and future technology
Expert Review of Medical Devices. 18(9):875-891 [DOI] 10.1080/17434440.2021.1962286.
2021
Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort.
Neurology. 96(4):e563-e574 [DOI] 10.1212/WNL.0000000000011049. [PMID] 33046615.
2021
Dystonia as a Presenting Feature of Acute Ischemic Stroke: A Case Report and Literature Review.
Cureus. 13(8) [DOI] 10.7759/cureus.17272. [PMID] 34540493.
2021
Encapsulated Peritoneal Sclerosis Masquerading as an Abdominal Catastrophe in Peritoneal Dialysis Therapy.
Cureus. 13(1) [DOI] 10.7759/cureus.12934. [PMID] 33654614.
2021
Evolution of Globus Pallidus Targeting for Parkinson’s and Dystonia Deep Brain Stimulation: A 15-Year Experience.
Frontiers in neurology. 12 [DOI] 10.3389/fneur.2021.679918. [PMID] 34456844.
2021
Moving From Wired to Wireless Brain Stimulation to Treat Movement Disorders: Are We Breaking Ground?
Movement disorders : official journal of the Movement Disorder Society. 36(3) [DOI] 10.1002/mds.28499. [PMID] 33548151.
2021
Predictive modelling of spread in adult-onset isolated dystonia: key properties and effect of tremor inclusion
European journal of neurology.. 28(12):3999-4009 [DOI] 10.1111/ene.15031. [PMID] 34296504.
2021
Proceedings of the Eighth Annual Deep Brain Stimulation Think Tank: Advances in Optogenetics, Ethical Issues Affecting DBS Research, Neuromodulatory Approaches for Depression, Adaptive Neurostimulation, and Emerging DBS Technologies.
Frontiers in human neuroscience. 15 [DOI] 10.3389/fnhum.2021.644593. [PMID] 33953663.
2021
Quality of life in isolated dystonia: non-motor manifestations matter.
Journal of neurology, neurosurgery, and psychiatry. [DOI] 10.1136/jnnp-2020-325193. [PMID] 33563813.
2021
The Gut-Brain Axis and Its Relation to Parkinson’s Disease: A Review.
Frontiers in aging neuroscience. 13 [DOI] 10.3389/fnagi.2021.782082. [PMID] 35069178.
2021
Time for a New 3-D Image for Globus Pallidus Internus Deep Brain Stimulation Targeting and Programming.
Journal of Parkinson's disease. 11(4):1881-1885 [DOI] 10.3233/JPD-212820. [PMID] 34420982.
2021
Transcranial Magnetic Stimulation in Tremor Syndromes: Pathophysiologic Insights and Therapeutic Role.
Frontiers in neurology. 12 [DOI] 10.3389/fneur.2021.700026. [PMID] 34512517.
2020
A pooled meta-analysis of GPi and STN deep brain stimulation outcomes for cervical dystonia.
Journal of neurology. 267(5):1278-1290 [DOI] 10.1007/s00415-020-09703-9. [PMID] 31938862.
2020
An International Survey of Deep Brain Stimulation Utilization in Asia and Oceania: The DBS Think Tank East.
Frontiers in human neuroscience. 14 [DOI] 10.3389/fnhum.2020.00162. [PMID] 32733215.
2020
Case Report: Globus Pallidus Internus (GPi) Deep Brain Stimulation Induced Keyboard Typing Dysfunction.
Frontiers in human neuroscience. 14 [DOI] 10.3389/fnhum.2020.583441. [PMID] 33240065.
2020
Chloroquine and hydroxychloroquine in the context of COVID-19.
Drugs in context. 9 [DOI] 10.7573/dic.2020-4-5. [PMID] 32373183.
2020
Clinical and imaging features of newly recognized Kelch-like protein 11 paraneoplastic syndrome.
Neurology. 95(3):134-135 [DOI] 10.1212/WNL.0000000000009895. [PMID] 32561677.
2020
Cognitive Outcomes for Essential Tremor Patients Selected for Thalamic Deep Brain Stimulation Surgery Through Interdisciplinary Evaluations.
Frontiers in human neuroscience. 14 [DOI] 10.3389/fnhum.2020.578348. [PMID] 33362489.
2020
Cortical Oscillations in Cervical Dystonia and Dystonic Tremor.
Cerebral cortex communications. 1(1) [DOI] 10.1093/texcom/tgaa048. [PMID] 32984818.
2020
Deep Brain Stimulation in Essential Tremor: Targets, Technology, and a Comprehensive Review of Clinical Outcomes
Expert Review of Neurotherapeutics. 20(4):319-331 [DOI] 10.1080/14737175.2020.1737017. [PMID] 32116065.
2020
Development and Validation of the Orthostatic Tremor Severity and Disability Scale (OT-10)
Movement Disorders. 35(10):1796-1801 [DOI] 10.1002/mds.28142. [PMID] 32562441.
2020
Dysarthria and Speech Intelligibility Following Parkinson’s Disease Globus Pallidus Internus Deep Brain Stimulation
Journal of Parkinson's disease (Online). 10(4):1493-1502 [DOI] 10.3233/JPD-202246. [PMID] 32955467.
2020
Effects of ventral intermediate nucleus deep brain stimulation across multiple effectors in essential tremor.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 131(1):167-176 [DOI] 10.1016/j.clinph.2019.10.019. [PMID] 31794958.
2020
Gait characterization for patients with orthostatic tremor
Parkinsonism & Related Disorders. 71:23-27 [DOI] 10.1016/j.parkreldis.2020.01.007.
2020
High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy.
Tremor and other hyperkinetic movements (New York, N.Y.). 10 [DOI] 10.7916/tohm.v0.749. [PMID] 32149014.
2020
Imaging of dopamine transporters in Parkinson disease: a meta-analysis of 18 F/123 I-FP-CIT studies.
Annals of clinical and translational neurology. 7(9):1524-1534 [DOI] 10.1002/acn3.51122. [PMID] 32794655.
2020
Longitudinal follow-up with VIM thalamic deep brain stimulation for dystonic or essential tremor.
Neurology. 94(10):e1073-e1084 [DOI] 10.1212/WNL.0000000000008875. [PMID] 32047071.
2020
Multidisciplinary Telemedicine Care for Tourette Syndrome: Minireview
Frontiers in Neurology. 11 [DOI] 10.3389/fneur.2020.573576. [PMID] 33391146.
2020
Potential role for rTMS in treating Primary Orthostatic Tremor
Brain Stimulation. 13(4):1105-1107 [DOI] 10.1016/j.brs.2020.05.004.
2020
Quantitative Separation of Tremor and Ataxia in Essential Tremor.
Annals of neurology. 88(2):375-387 [DOI] 10.1002/ana.25781. [PMID] 32418250.
2020
Reply to letter to the editor, “A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia.”.
Parkinsonism & related disorders. 74 [DOI] 10.1016/j.parkreldis.2020.01.014. [PMID] 32127261.
2020
Secondary Worsening Following DYT1 Dystonia Deep Brain Stimulation: A Multi-country Cohort.
Frontiers in human neuroscience. 14 [DOI] 10.3389/fnhum.2020.00242. [PMID] 32670041.
2020
STN Versus GPi Deep Brain Stimulation for Action and Rest Tremor in Parkinson’s Disease.
Frontiers in human neuroscience. 14 [DOI] 10.3389/fnhum.2020.578615. [PMID] 33192410.
2020
Therapeutic Advances in the Treatment of Holmes Tremor: Systematic Review
Neuromodulation. 25(6):796-803 [DOI] 10.1111/ner.13220. [PMID] 32578304.
2019
A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia
Parkinsonism & Related Disorders. 63:195-198 [DOI] 10.1016/j.parkreldis.2019.02.035.
2019
Cortical dynamics within and between parietal and motor cortex in essential tremor.
Movement disorders : official journal of the Movement Disorder Society. 34(1):95-104 [DOI] 10.1002/mds.27522. [PMID] 30345712.
2019
Essential requisites for rest tremor assessment in Parkinson’s disease.
Movement disorders : official journal of the Movement Disorder Society. 34(6):927-929 [DOI] 10.1002/mds.27711. [PMID] 31206835.
2019
Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.
Drugs in context. 8 [DOI] 10.7573/dic.2019-9-1. [PMID] 31844421.
2019
Gait worsening and the microlesion effect following deep brain stimulation for essential tremor.
Journal of neurology, neurosurgery, and psychiatry. 90(8):913-919 [DOI] 10.1136/jnnp-2018-319723. [PMID] 30846538.
2019
Importance of the initial response to GPi deep brain stimulation in dystonia: A nine year quality of life study
Parkinsonism & Related Disorders. 64:249-255 [DOI] 10.1016/j.parkreldis.2019.04.024.
2019
Network-level connectivity is a critical feature distinguishing dystonic tremor and essential tremor.
Brain : a journal of neurology. 142(6):1644-1659 [DOI] 10.1093/brain/awz085. [PMID] 30957839.
2019
Reply: Thalamotomy for tremor normalizes aberrant pre-therapeutic visual cortex functional connectivity.
Brain : a journal of neurology. 142(11) [DOI] 10.1093/brain/awz300. [PMID] 31603506.
2019
Sniffing out cognitive decline in patients with or without evidence of dopaminergic deficit
Clinical Parkinsonism & Related Disorders. 1:77-81
2019
Square Biphasic Pulse Deep Brain Stimulation for Parkinson’s Disease: The BiP-PD Study.
Frontiers in human neuroscience. 13 [DOI] 10.3389/fnhum.2019.00368. [PMID] 31680918.
2019
STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: A systematic review and meta-analysis
Parkinsonism & Related Disorders. 58:56-62 [DOI] 10.1016/j.parkreldis.2018.08.017. [PMID] 30177491.
2018
A widespread visually-sensitive functional network relates to symptoms in essential tremor.
Brain : a journal of neurology. 141(2):472-485 [DOI] 10.1093/brain/awx338. [PMID] 29293948.
2018
Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm
Brain Stimulation. 11(3):645-647 [DOI] 10.1016/j.brs.2018.02.004.
2018
Deep Brain Stimulation at Variable Frequency to Improve Motor Outcomes in Parkinson’s Disease.
Movement disorders clinical practice. 5(5):538-541 [DOI] 10.1002/mdc3.12658. [PMID] 30637270.
2018
Deep Brain Stimulation in Parkinson’s Disease.
Parkinson's disease. 2018:9625291-2 [DOI] 10.1155/2018/9625291. [PMID] 29755729.
2018
Deep Brain Stimulation in Parkinson’s Disease
Parkinson's Disease. 2018:1-2 [DOI] 10.1155/2018/9625291. [PMID] 29755729.
2018
Globus Pallidum DBS for Task-Specific Dystonia in a Professional Golfer.
Tremor and other hyperkinetic movements (New York, N.Y.). 8 [DOI] 10.7916/D83X9Q9D. [PMID] 30402336.
2018
Globus pallidus internus deep brain stimulation induces tremor in Parkinson’s disease: A paradoxical phenomenon
Journal of the Neurological Sciences. 392:102-104 [DOI] 10.1016/j.jns.2018.07.005.
2018
Is deep brain stimulation therapy underutilized for movement disorders?
Expert review of neurotherapeutics. 18(12):899-901 [DOI] 10.1080/14737175.2018.1538791. [PMID] 30350730.
2018
Microlesion effects, suboptimal lead placement and disease progression are critical determinants for DBS tolerance in essential tremor.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 129(10):2215-2216 [DOI] 10.1016/j.clinph.2018.07.024. [PMID] 30131211.
2018
Physiological effects of subthalamic nucleus deep brain stimulation surgery in cervical dystonia.
Journal of neurology, neurosurgery, and psychiatry. 89(12):1296-1300 [DOI] 10.1136/jnnp-2017-317098. [PMID] 29326293.
2018
Rationale and patient selection for interventional therapies in Parkinson’s disease.
Expert review of neurotherapeutics. 18(11):811-823 [DOI] 10.1080/14737175.2018.1535902. [PMID] 30328737.
2018
Reply: Visually-sensitive networks in essential tremor: evidence from structural and functional imaging.
Brain : a journal of neurology. 141(6) [DOI] 10.1093/brain/awy096. [PMID] 29659746.
2018
Square biphasic pulse deep brain stimulation for essential tremor: The BiP tremor study.
Parkinsonism & related disorders. 46:41-46 [DOI] 10.1016/j.parkreldis.2017.10.015. [PMID] 29102253.
2018
Th17 lymphocyte spearheads the immune attack in Parkinson’s disease: New evidence for neuronal death.
Movement disorders : official journal of the Movement Disorder Society. 33(10) [DOI] 10.1002/mds.27496. [PMID] 30365216.
2018
Ventral Intermediate Nucleus Versus Zona Incerta Region Deep Brain Stimulation in Essential Tremor.
Movement disorders clinical practice. 5(1):75-82 [DOI] 10.1002/mdc3.12565. [PMID] 30363386.
2017
A Randomized Trial of Relamorelin for Constipation in Parkinson’s Disease (Move-Pd): Trial Results and Lessons Learned
Parkinsonism & Related Disorders. 37:101-105 [DOI] 10.1016/j.parkreldis.2017.02.003.
2017
ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia-Reply.
JAMA neurology. 74(12) [DOI] 10.1001/jamaneurol.2017.3211. [PMID] 29114722.
2017
Botulinum Toxin Therapy for Parkinson’s Disease.
Seminars in neurology. 37(2):193-204 [DOI] 10.1055/s-0037-1602246. [PMID] 28511260.
2017
Cognitive Impact of Deep Brain Stimulation on Parkinson’s Disease Patients
Parkinson's Disease. 2017:1-15 [DOI] 10.1155/2017/3085140. [PMID] 29359065.
2017
Complex genetics of Tourette’s Syndrome: Piecing the puzzle.
Movement disorders : official journal of the Movement Disorder Society. 32(12) [DOI] 10.1002/mds.27218. [PMID] 29131391.
2017
DBS Programming: An Evolving Approach for Patients with Parkinson’s Disease
Parkinson's Disease. 2017:1-11 [DOI] 10.1155/2017/8492619. [PMID] 29147598.
2017
Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost?
JAMA neurology. 74(8):904-905 [DOI] 10.1001/jamaneurol.2017.0954. [PMID] 28604930.
2017
Focal cervical dystonia presents in the setting of acute cerebellar hemorrhage
Journal of the Neurological Sciences. 375:307-308 [DOI] 10.1016/j.jns.2016.12.037.
2017
Functional activity of the sensorimotor cortex and cerebellum relates to cervical dystonia symptoms.
Human brain mapping. 38(9):4563-4573 [DOI] 10.1002/hbm.23684. [PMID] 28594097.
2017
Thalamic deep brain stimulation for orthostatic tremor: A multicenter international registry.
Movement disorders : official journal of the Movement Disorder Society. 32(8):1240-1244 [DOI] 10.1002/mds.27082. [PMID] 28631862.
2017
The ice test to differentiate essential tremor from Parkinson’s disease tremor.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 128(11):2181-2183 [DOI] 10.1016/j.clinph.2017.08.015. [PMID] 28946133.
2017
Variable frequency stimulation of subthalamic nucleus in Parkinson’s disease: Rationale and hypothesis.
Parkinsonism & related disorders. 39:27-30 [DOI] 10.1016/j.parkreldis.2017.03.015. [PMID] 28392298.
2017
Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.
Neurology. Clinical practice. 7(4):283-295 [DOI] 10.1212/CPJ.0000000000000371. [PMID] 28840919.
2016
Association between antidepressants and falls in Parkinson’s disease.
Journal of neurology. 263(1):76-82 [DOI] 10.1007/s00415-015-7947-5. [PMID] 26514836.
2016
Benign tremulous Parkinsonism: a unique entity or another facet of Parkinson’s disease?
Translational neurodegeneration. 5 [DOI] 10.1186/s40035-016-0057-1. [PMID] 27213042.
2016
Deep Brain Stimulation in a Case of Mitochondrial Disease.
Movement disorders clinical practice. 3(2):139-145 [DOI] 10.1002/mdc3.12241. [PMID] 30713906.
2016
Erratum to: Variables associated with physical health-related quality of life in Parkinson’s disease patients presenting for deep brain stimulation.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 37(11):1839-1840 [PMID] 27562296.
2016
High rates of fatigue and sleep disturbances in dystonia.
The International journal of neuroscience. 126(10):928-35 [DOI] 10.3109/00207454.2015.1085035. [PMID] 26289935.
2016
Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial.
Neurology. 87(18):1907-1915 [PMID] 27708129.
2016
Occurrence of Dysphagia Following Botulinum Toxin Injection in Parkinsonism-related Cervical Dystonia: A Retrospective Study.
Tremor and other hyperkinetic movements (New York, N.Y.). 6 [PMID] 27830106.
2016
Proceedings of the Fourth Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies.
Frontiers in integrative neuroscience. 10 [PMID] 27920671.
2016
Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy in Parkinson Disease: A Meta-Analysis.
PM & R : the journal of injury, function, and rehabilitation. 8(4):356-366 [DOI] 10.1016/j.pmrj.2015.08.009. [PMID] 26314233.
2016
State of the Art for Deep Brain Stimulation Therapy in Movement Disorders: A Clinical and Technological Perspective
IEEE Reviews in Biomedical Engineering. 9:219-233 [DOI] 10.1109/rbme.2016.2588399.
2016
State of the Art for Deep Brain Stimulation Therapy in Movement Disorders: A Clinical and Technological Perspective
IEEE Reviews in Biomedical Engineering. 9:219-233 [DOI] 10.1109/rbme.2016.2588399.
2016
Variables associated with physical health-related quality of life in Parkinson’s disease patients presenting for deep brain stimulation.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 37(11):1831-1837 [PMID] 27457654.
2015
Abnormal tactile pressure perception in Parkinson’s disease.
Journal of clinical and experimental neuropsychology. 37(8):808-15 [DOI] 10.1080/13803395.2015.1060951. [PMID] 26313511.
2015
Functional Brain Activity Relates to 0-3 and 3-8 Hz Force Oscillations in Essential Tremor.
Cerebral cortex (New York, N.Y. : 1991). 25(11):4191-202 [DOI] 10.1093/cercor/bhu142. [PMID] 24962992.
2015
Global attentional neglect of segmented lines in Parkinson’s disease.
Neurocase. 21(4):501-8 [DOI] 10.1080/13554794.2014.942671. [PMID] 25073971.
2015
Missing dosages and neuroleptic usage may prolong length of stay in hospitalized Parkinson’s disease patients.
PloS one. 10(4) [DOI] 10.1371/journal.pone.0124356. [PMID] 25884484.
2015
Rate of aspiration pneumonia in hospitalized Parkinson’s disease patients: a cross-sectional study.
BMC neurology. 15 [DOI] 10.1186/s12883-015-0362-9. [PMID] 26141135.
2015
Unexpected dual task benefits on cycling in Parkinson disease and healthy adults: a neuro-behavioral model.
PloS one. 10(5) [DOI] 10.1371/journal.pone.0125470. [PMID] 25970607.
2015
Update on deep brain stimulation in Parkinson’s disease.
Translational neurodegeneration. 4 [DOI] 10.1186/s40035-015-0034-0. [PMID] 26257895.
2014
An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting.
PloS one. 9(3) [DOI] 10.1371/journal.pone.0091545. [PMID] 24646688.
2014
Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis.
Tremor and other hyperkinetic movements (New York, N.Y.). 4 [DOI] 10.7916/D8H41Q4X. [PMID] 25562037.
2014
Defining the clinically meaningful difference in gait speed in persons with Parkinson disease.
Journal of neurologic physical therapy : JNPT. 38(4):233-8 [DOI] 10.1097/NPT.0000000000000055. [PMID] 25198866.
2014
Surgical treatment of Parkinson’s disease: patients, targets, devices, and approaches.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 11(1):47-59 [DOI] 10.1007/s13311-013-0235-0. [PMID] 24198187.
2014
The “brittle response” to Parkinson’s disease medications: characterization and response to deep brain stimulation.
PloS one. 9(4) [DOI] 10.1371/journal.pone.0094856. [PMID] 24733172.
2014
Treatment and physiology in Parkinson’s disease and dystonia: using transcranial magnetic stimulation to uncover the mechanisms of action.
Current neurology and neuroscience reports. 14(6) [DOI] 10.1007/s11910-014-0449-5. [PMID] 24771105.
2013
Driving performance and behaviors: a comparison of gender differences in Parkinson’s disease.
Traffic injury prevention. 14(4):340-5 [DOI] 10.1080/15389588.2012.717730. [PMID] 23531256.
2013
Impact of discontinuing tremor suppressing medications following thalamic deep brain stimulation.
Parkinsonism & related disorders. 19(2):171-5 [DOI] 10.1016/j.parkreldis.2012.09.002. [PMID] 23062997.
2013
Long-term subthalamic nucleus stimulation improves sensorimotor integration and proprioception.
Journal of neurology, neurosurgery, and psychiatry. 84(9):1020-8 [DOI] 10.1136/jnnp-2012-304102. [PMID] 23616568.
2013
Postural/Gait and cognitive function as predictors of driving performance in Parkinson’s disease.
Journal of Parkinson's disease. 3(2):153-60 [DOI] 10.3233/JPD-120152. [PMID] 23938345.
2013
Unilateral thalamic deep brain stimulation in essential tremor demonstrates long-term ipsilateral effects.
Parkinsonism & related disorders. 19(12):1113-7 [DOI] 10.1016/j.parkreldis.2013.08.001. [PMID] 24021661.
2012
A case of an arachnoid cyst masquerading as corticobasal degeneration.
The Clinical neuropsychologist. 26(8):1342-57 [DOI] 10.1080/13854046.2012.728247. [PMID] 23061395.
2012
Emerging opportunities for serotypes of botulinum neurotoxins.
Toxins. 4(11):1196-222 [DOI] 10.3390/toxins4111196. [PMID] 23202312.
2012
Fatigue, Sleepiness and Sleep Issues in Patients With Dystonia
. 78
2012
Micrographia and related deficits in Parkinson’s disease: a cross-sectional study.
BMJ open. 2(3) [DOI] 10.1136/bmjopen-2011-000628. [PMID] 22734114.
2012
Personalized Medicine in Deep Brain Stimulation Through Utilization of Neural Oscillations
. 78:1900-1901
2012
Personalized medicine in deep brain stimulation through utilization of neural oscillations.
Neurology. 78(24):1900-1 [DOI] 10.1212/WNL.0b013e318259e2af. [PMID] 22592364.
2012
Quantitative normative gait data in a large cohort of ambulatory persons with Parkinson’s disease.
PloS one. 7(8) [DOI] 10.1371/journal.pone.0042337. [PMID] 22879945.
2012
Worsening essential tremor following deep brain stimulation: disease progression versus tolerance.
Brain : a journal of neurology. 135(Pt 5):1455-62 [DOI] 10.1093/brain/aws026. [PMID] 22344584.

Grants

Sep 2022 ACTIVE
Progressive resistance exercise and dystonia pathophysiology.
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
May 2022 ACTIVE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of PRAX-944 in the Treatment of Adults with Essential Tremor
Role: Principal Investigator
Funding: SYNEOS HEALTH via PRAXIS PRECISION MEDICINES
Apr 2022 ACTIVE
CTOA – Shukla CT salary
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Dec 2021 – May 2022
STOP-TIC Study: F014647 Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT
Role: Other
Funding: UF FOUNDATION
Dec 2021 – May 2022
STOP-TIC Study: Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT
Role: Other
Funding: UF FOUNDATION
Jul 2021 ACTIVE
Synergism of botulinum toxin and repetitive transcranial magnetic stimulation for motor and non-motor symptoms of cervical dystonia
Role: Principal Investigator
Funding: DYSTONIA MEDICAL RES FOU
May 2021 ACTIVE
Cerebellar and Basal Ganglia Markers Underlie Neuromotor Impairments in Adults with Autism Spectrum Disorder (ASD)
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jun 2020 – May 2022
A PHASE 2, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF SAGE-324 IN THE TREATMENT OF INDIVIDUALS WITH ESSENTIAL TREMOR
Role: Principal Investigator
Funding: SYNEOS HEALTH via SAGE THERAPEUTICS INC
Sep 2019 ACTIVE
Dystonia Coalition Projects-3
Role: Principal Investigator
Funding: DYSTONIA MEDICAL RES FOU via NATL INST OF HLTH NCATS
Jul 2016 – Jun 2021
Functional Brain networks in essential Tremor and dystonic tremor
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2016 – Sep 2018
Physiological effects of Botulinum Toxin therapy in Primary Cervical Dystonia
Role: Other
Funding: DYSTONIA MEDICAL RES FOU
Feb 2016 – Feb 2019
A PHASE 2,OPEN-LABEL,DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY & PRELIMINARY EFFICACY OF RTT150 FOR INJECTION IN …
Role: Principal Investigator
Funding: PHARM OLAM
Aug 2015 – Nov 2015
A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinsons Disease Patients With Motor Response Fluctuations (OFF Phenomena)
Role: Principal Investigator
Funding: CIVITAS THERAPEUTICS INC
Jul 2015 – Jun 2017
Combined therapy with rTMS and botulinum toxin in primary cervical dystonia
Role: Principal Investigator
Funding: AMER ACAD OF NEUROLOGY
Mar 2015 – Nov 2018
G??rTMS therapy for primary orthostatic tremor: A novel treatment approachG??
Role: Principal Investigator
Funding: National Organization for Rare Disorders
Jan 2015 – Apr 2017
Combined effects of rTMS and botulinum toxin in benign essential blepharospasm: A novel approach
Role: Principal Investigator
Funding: Benign Essential Blepharospasm Res Fou
Jul 2014 – Jun 2016
UFF Companion Project to ABF 2014 Clinical Research Training Fellowship in Neurotoxins
Role: Principal Investigator
Funding: UF FOUNDATION
Jun 2013 – Feb 2016
A PHASE IIIb, prospective, MULTICENTRE, open-label EXTENSION STUDY TO ASSESS LONG TERM SAFETY AND EFFECTIVENESS OF DYSPORT
Role: Principal Investigator
Funding: IPSEN BIOPHARMACEUTICALS
May 2013 – Feb 2016
A PHASE IIIb, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF DYSPORT USING 2 mL DILUTION IN ADULTS WITH CERVICAL DYSTONIA
Role: Principal Investigator
Funding: IPSEN BIOPHARMACEUTICALS
Nov 2011 – Oct 2016
Magnetic Stimulation for the Treatment of Motor and Mood Symptoms of Parkinsons Disease: A Four-Center, Sham-Controlled, Parallel Group Study-Cost Share
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2006 ACTIVE
BRAIN AND SPINAL CORD INJURY RESEARCH
Role: Project Manager
Funding: FL DEPT OF HLTH

Education

Residency – Neurology
2006-2010 · University of Arkansas
Fellowship
2003-2006 · University of Toronto
Medical School
1996 · NHL MMC, India

Contact Details

Phones:
Business:
(352) 273-5550
Addresses:
Business Mailing:
PO Box 100268
GAINESVILLE FL 32610
Business Street:
3011 SW WILLISTON RD RM 1103
GAINESVILLE FL 32608